- Home
- LPSN vs MAIA Comparison
LPSN vs MAIA Comparison
Compare LPSN & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPSN | MAIA |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 49.3M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LPSN | MAIA |
|---|---|---|
| Price | $3.28 | $2.40 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 211.4K | ★ 879.1K |
| Earning Date | 03-04-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,660,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.94 | $0.87 |
| 52 Week High | $23.55 | $2.74 |
Technical Indicators
Market Signals| Indicator | LPSN | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 73.94 |
| Support Level | $2.94 | $1.49 |
| Resistance Level | $4.12 | $2.34 |
| Average True Range (ATR) | 0.22 | 0.17 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 29.11 | 91.28 |
Price Performance
Historical ComparisonAbout LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.